Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Completed Phase 3 Trials for Meningococcal Infections Prevention

CompletedPrevention3 IdentifierTitleDrugs
NCT02986854Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
NCT00616421Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children